StockNews.com Upgrades Cytosorbents (NASDAQ:CTSO) to “Hold”

Cytosorbents (NASDAQ:CTSO – Get Rating) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Friday.

Cytosorbents Price Performance

NASDAQ CTSO opened at $3.58 on Friday. The stock has a market capitalization of $156.23 million, a PE ratio of -4.77 and a beta of 0.77. Cytosorbents has a 12-month low of $1.03 and a 12-month high of $4.59. The company has a 50 day moving average price of $2.87 and a two-hundred day moving average price of $2.02.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds have recently made changes to their positions in CTSO. Skylands Capital LLC boosted its stake in shares of Cytosorbents by 8.3% in the 4th quarter. Skylands Capital LLC now owns 2,542,091 shares of the medical research company’s stock valued at $3,940,000 after purchasing an additional 195,057 shares during the last quarter. Avenir Corp raised its holdings in Cytosorbents by 5.7% during the 4th quarter. Avenir Corp now owns 2,447,089 shares of the medical research company’s stock worth $3,793,000 after buying an additional 132,235 shares during the period. Granahan Investment Management LLC raised its holdings in Cytosorbents by 5.5% during the 4th quarter. Granahan Investment Management LLC now owns 1,593,711 shares of the medical research company’s stock worth $2,470,000 after buying an additional 82,682 shares during the period. Neuberger Berman Group LLC raised its holdings in shares of Cytosorbents by 3.3% in the fourth quarter. Neuberger Berman Group LLC now owns 1,529,095 shares of the medical research company’s stock valued at $2,327,000 after purchasing an additional 49,525 shares during the last quarter. Finally, Sargent Investment Group LLC raised its holdings in shares of Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,108,233 shares of the medical research company’s stock valued at $2,028,000 after purchasing an additional 130,737 shares during the last quarter. Institutional investors and hedge funds own 34.04% of the company’s stock.

Cytosorbents Company Profile

(Get Rating)

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.